Consultation on the Reimbursement Committee’s recommendation concerning the reimbursement status of medicinal products in ATC groups A04 (antiemetics and antinauseants) and A03FA (propulsives)
At the Danish Medicines Agency’s request, the Reimbursement Committee has reassessed the reimbursement status of medicinal products authorised for marketing in Denmark in ATC groups A04 (antiemetics and antinauseants) and A03FA (propulsives).
The Reimbursement Committee’s recommendation can be read in the factbox to the right (in Danish only). The recommendation contains a list of links to the references which the Reimbursement Committee has emphasised in its recommendation.
On 25 June 2009, the Danish Medicines Agency launched a consultation of the companies whose medicinal products are comprised by the Committee’s recommendation. A copy of the Danish Medicines Agency’s letter can be seen in the factbox to the right (in Danish only).
The consultation is open until Monday 17 August 2009.
Moreover, we have sent a notification about the Reimbursement Committee’s recommendation to the Danish Society for Gastroenterology, Danish Surgical Society, Danish Medical Society, Danish College of General Practitioners Danish Society of Internal Medicine, Danish Society of Clinical Pharmacology, Danish Society of Clinical Oncology and Danish Society of Palliative Medicine. In addition, the National Board of Health and the Institute for Rational Pharmacotherapy have been briefed.
For further information, please contact the Reimbursement Department at email@example.com.
Danish Medicines Agency, 26 June 2009